araag2/HINT huggingface dataset:
Clinical trial NCT00193128 (phase 1/phase 2, status: completed)
Conditions: esophagus cancer
ICD codes: D13.0, C15.9, C15.3, C15.4, C15.5, C15.8, Z85.01
Drugs: oxaliplatin, docetaxel, capecitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

        To be included in this study, you must meet the following criteria:

          -  Adenocarcinoma or squamous cell carcinoma of the esophagus or G/E junction.

          -  Must be surgical candidates

          -  No previous treatment for esophageal cancer

          -  Must have measurable or evaluable disease

          -  Able to perform activities of daily living with minimal to no assistance

          -  Adequate bone marrow, liver and kidney function

          -  Provide written informed consent

        Exclusion Criteria:

        You cannot participate in this study if any of the following apply to you:

          -  Tumor location in the proximal esophagus

          -  Metastatic disease or locally advanced cancer

          -  Moderate to severe peripheral neuropathy

          -  Serious pre-existing medical illnesses

          -  Significant heart disease

          -  Treated for an invasive cancer within the previous 5 years

          -  Women who are pregnant or breast-feeding

          -  Age < 18 years

        Please note: There are additional inclusion/exclusion criteria. The study center will
        determine if you meet all of the criteria. If you do not qualify for the trial, study
        personnel will explain the reasons. If you do qualify, study personnel will explain the
        trial in detail and answer any questions you may have.
Clinical trial NCT00356928 (phase 1, status: terminated)
Conditions: leukemia, myelodysplastic syndromes
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, D46.9, D46.C, D46.Z
Drugs: cyclophosphamide
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following:

               -  Myelodysplastic syndromes (MDS)

                    -  International Prognostic Scoring System (IPSS) score ≥ intermediate-2

               -  Chronic myelomonocytic leukemia

               -  Acute myeloid leukemia arising from MDS

          -  Must have failed or are ineligible for or intolerant to treatment with azacitidine

               -  Patients with normal marrow cytogenetics or an isolated 5q- abnormality must have
                  failed or are ineligible for or intolerant to treatment with lenalidomide

               -  Patients who are HLA-DR15-positive must have failed or are ineligible for
                  pharmacologic immunosuppression (e.g., anti-thymocyte globulin, cyclosporine,
                  steroids)

          -  No presence of cytotoxic antibodies against donor lymphocytes

          -  No HLA-identical donor available OR ineligible for HLA-identical allogeneic bone
             marrow transplantation

          -  HLA partially mismatched (haploidentical) related donor available

               -  First-degree related donor, including half-siblings or first cousins

               -  Inherited recombinant haplotype from parents allowed if donor shares ≥ 1 HLA
                  antigen at each of the HLA-A, -B, and DR loci

        PATIENT CHARACTERISTICS:

          -  ECOG performance status (PS) 0-1 OR Karnofsky PS 80-100%

          -  Bilirubin < 3.0 mg/dL

          -  AST and ALT ≤ 4 times upper limit of normal

          -  Creatinine < 3.0 mg/dL

          -  LVEF > 35%

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  Recovered from prior therapy

          -  No prior transfusions from donor

          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or
             radiotherapy

          -  No other concurrent investigational drugs
Clinical trial NCT00372515 (phase 1, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: gefitinib
SMILES: COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically proven diagnosis of non-small cell lung cancer of any
             histologic subtype

          -  High likelihood of gefitinib sensitivity, as evidenced by one or more of the
             following: previous complete or partial response to treatment with an epidermal growth
             factor receptor-tyrosine kinase inhibitor, erlotinib, or gefitinib; known somatic
             mutation of the EGFR tyrosine kinase

          -  Recurrent or persistent disease as manifested by carcinomatous meningitis

          -  ECOG PS 0-3

          -  Age 18 years or older

          -  Greater than 2 weeks since prior radiation therapy

          -  Greater than 3 weeks since prior major surgery

          -  Adequate hematologic, renal, and/or hepatic function

          -  Coagulation parameters: international normalized ratio(INR)less than or equal to 1.5
             and an activated thromboplastin time < 50 seconds

        Exclusion Criteria:

          -  Previous Grade 4 toxicity on gefitinib or erlotinib leading to dose reduction or
             interruption

          -  Uncontrolled brain metastases, or brain metastases associated with mass effect that
             would contraindicate lumbar puncture

          -  Any other malignancy within the past five years, except for adequately treated
             carcinoma of the cervix, basal or squamous cell carcinomas of the skin

          -  Dysphagia

          -  Active gastrointestinal disease or disorder that alters gastrointestinal motility or
             absorption

          -  Incomplete healing from previous oncologic or other major surgery

          -  Any pre-existing severe or unstable medical condition

          -  Any condition requiring concurrent and ongoing use of anticoagulation

          -  Inability to undergo collection of CSF, either by repeated lumbar puncture or
             placement of an Omaya reservoir

          -  Pregnant or breastfeeding

          -  Concurrent intrathecal drug administration or radiotherapy

          -  Concurrent systemic chemotherapy or investigational agent

          -  Anticoagulant except aspirin or heparin flushes

          -  Enzyme-inducing anti-epileptic drug

          -  CYP3A4 inhibitors
Clinical trial NCT00528281 (phase 1, status: completed)
Conditions: lung cancer, non-small cell
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: lapatinib, pemetrexed
SMILES: CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        INCLUSION CRITERIA:

          -  Signed informed consent;

          -  Patients must be 18 years old;

          -  Subjects must have stage IIIB or IV NSCLC .

          -  Recurrent or persistent NSCLC following one previous line of cytotoxic chemotherapy.

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2;

          -  Life expectancy of 12 weeks;

          -  Have adequate organ function baseline laboratory values for inclusion;

        EXCLUSION CRITERIA:

          -  History of other malignancy. Subjects who have been disease-free for 5 years, or
             subjects with a history of completely resected non-melanoma skin cancer or
             successfully treated in situ carcinoma are eligible;

          -  Known history of or clinical evidence of central nervous system (CNS) metastases or
             leptomeningeal carcinomatosis except for individuals who have previously treated CNS
             metastases, are asymptomatic, and have had no requirement for steroids or antiseizure
             medication for = 3 months prior to study enrollment.

          -  Peripheral neuropathy of grade 3 or higher;

          -  Concurrent cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy,
             biologic therapy, hormonal therapy, and tumor embolization).

          -  Prior exposure to pemetrexed or an EGFR inhibitor in combination with 5-FU or a 5FU
             prodrug.
Clinical trial NCT00310050 (phase 1, status: terminated)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: pemetrexed disodium
SMILES: [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed carcinoma arising from the pancreas

               -  Stage II or III disease, meeting 1 of the following criteria:

                    -  Nonresectable disease

                    -  Potentially resectable disease

                    -  Resectable disease

               -  Stage IV disease with symptomatic back pain requiring palliation allowed at the
                  discretion of the principal investigator

          -  Measurable, evaluable, or nonmeasurable disease

          -  No neuroendocrine tumor of the pancreas

          -  No documented brain metastasis

          -  No clinically significant pleural or peritoneal effusions that cannot be drained

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  Life expectancy ≥ 12 weeks

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Hemoglobin ≥ 9 g/dL

          -  Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  Alkaline phosphatase ≤ 3 times ULN (5 times ULN if liver has tumor involvement)

          -  AST and ALT ≤ 3 times ULN (5 times ULN if liver has tumor involvement)

          -  Creatinine clearance ≥ 45 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 3 months after
             completion of study treatment

          -  No active infection

          -  No serious systemic disorders that would preclude study treatment

          -  No significant cardiovascular disease in the form of abnormal electrocardiogram
             coupled with clinical features of recent or recurrent cardiac disease (including
             myocardial infarction, angina, or hypertension)

        PRIOR CONCURRENT THERAPY:

          -  More than 4 weeks since prior investigational agents

          -  No prior chemotherapy for pancreatic cancer

          -  Must be able to discontinue aspirin, dexamethasone, and other nonsteroidal
             anti-inflammatory agents for 2 days before, the day of, and 2 days after pemetrexed
             disodium dose (5 days before for long-acting agents such as piroxicam)

          -  Must be able and willing to take folic acid and cyanocobalamin (vitamin B12)
             supplementation
Clinical trial NCT00412464 (phase 1, status: completed)
Conditions: thrombosis, heparin-induced thrombocytopenia
ICD codes: I81, K64.5, I51.3, I67.6, I74.11, I74.5, I74.8, D75.82
Drugs: fondaparinux
SMILES: CO[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C@H]3O[C@H](COS(O)(=O)=O)[C@@H](O[C@@H]4O[C@@H]([C@@H](O[C@H]5O[C@H](COS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H]5NS(O)(=O)=O)[C@H](O)[C@H]4O)C(O)=O)[C@H](OS(O)(=O)=O)[C@H]3NS(O)(=O)=O)[C@H](O)[C@H]2OS(O)(=O)=O)C(O)=O)[C@H](O)[C@H]1NS(O)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Children between 1 year and 18 years of age.

          -  The presence of documented venous or arterial thrombosis confirmed by diagnostic
             imaging.

          -  Weight greater than 8.3 kg.

          -  Signed informed consent/assent.

        Exclusion Criteria:

          -  Patients with active bleeding.

          -  Patients with planned invasive procedures less than 2 weeks from the time of
             enrollment.

          -  Patients with a contraindication to anticoagulation.

          -  Patients receiving thrombolytic agents.

          -  Patients with an INR>1.5 or an activated partial thromboplastin time (PTT)>40 seconds.

          -  Patients with a creatinine level above 1.2 times the upper limit of normal expected
             for age.

          -  Children <1 year of age.
Clinical trial NCT01171924 (phase 1, status: completed)
Conditions: head and neck cancer, liver cancer, breast cancer, gastric cancer, non-small cell lung cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11, D13.4, Z85.05, C22.8, C78.7, C22.9, D37.6, C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: cudc-101, cudc-101
SMILES: COC1=C(OCCCCCCC(=O)NO)C=C2C(NC3=CC=CC(=C3)C#C)=NC=NC2=C1, COC1=C(OCCCCCCC(=O)NO)C=C2C(NC3=CC=CC(=C3)C#C)=NC=NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with histopathologically confirmed diagnosis of advanced breast, gastric,
             head and neck, liver and non-small cell lung cancer.

               -  For subjects with non-small cell lung cancer only:

                    -  Most recent treatment must be erlotinib and subjects must have had a
                       radiographic partial or complete response to treatment as defined by RECIST
                       criteria and should be currently progressing after the documented response.

                    -  A documented mutation in EGFR exons 19 or 21

          -  Subjects must have no further standard of care options or have refused standard
             therapy

          -  Measurable or evaluable disease

          -  Age ≥ 18 years

          -  ECOG performance < 2

          -  Life expectancy ≥ 3 months

          -  If female, neither pregnant or lactating

          -  If of child bearing potential, must use adequate birth control

          -  Absolute neutrophil count ≥ 1,500/µL; platelets ≥ 100,000/µL;

          -  Creatinine ≤ 1.5x upper limit of normal (ULN) or calculated creatinine clearance ≥
             60mL/min/1.73m2

          -  Total bilirubin ≤ 1.5x ULN; AST/ALT ≤ 2.5x ULN. In subjects with documented liver
             metastases, the AST/ALT may be ≤ 5x ULN

          -  Prothrombin time ≤1.5x ULN, unless receiving therapeutic anticoagulation

          -  Serum magnesium and potassium within normal limits (may use supplements to achieve
             normal values)

          -  Subjects with brain metastases are eligible if controlled on a stable dose ≤ 10mg
             prednisone/day or its equivalent dose of steroids

          -  Able to render informed consent and to follow protocol requirements.

        Exclusion Criteria:

          -  Anticancer therapy within 4 weeks of study entry.

          -  Use of investigational agent(s) within 30 days of study entry

          -  History of cardiac disease with a New York Heart Association (NYHA) Class II or
             greater congestive heart failure (CHF), myocardial infarction (MI) or unstable angina
             in the past 6 months prior to Day 1 of treatment, serious arrhythmias requiring
             medication for treatment.

          -  Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
             Subjects with liver cancer and hepatitis may be eligible.
Clinical trial NCT00141037 (phase 1/phase 2, status: completed)
Conditions: kidney diseases, kidney transplantation, kidney transplant, renal transplantation, renal transplant
ICD codes: I12.9, N18.9, Q61.9, I12.0, D63.1, N18.1, N18.5, N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0, T86.11, T86.12, T86.13, Z94.0, T86.10, T86.19, Z48.22, N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1, N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: daclizumab, mycophenolate mofetil (mmf), prednisone, tacrolimus, ganciclovir, valganciclovir, trimethoprim and sulfamethoxazole
SMILES: COC(=O)\C=C\C(O)=O, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1, CC(C)[C@H](N)C(=O)OCC(CO)OCN1C=NC2=C1NC(N)=NC2=O, CC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NO1
Eligibility criteria:

        Inclusion Criteria:

          -  Primary recipient of a kidney transplant

          -  Meets site-specific transplant criteria

          -  Panel Reactive Antibody (PRA) of 20% or less

          -  Willing to use acceptable forms of contraception

          -  Parent or guardian willing to provide informed consent, if applicable

        Exclusion Criteria:

          -  Previous treatment with steroids within 6 months prior to transplantation

          -  Received en-bloc kidney or other kidney that does not meet protocol-specified
             requirements

          -  Received an organ from an human leukocyte antigen (HLA) identical donor or a
             non-heart-beating donor

          -  Received a solid organ other than a kidney

          -  Received a bone marrow or hematopoietic stem cell transplant

          -  Received a repeat kidney transplant

          -  Currently receiving an investigational pharmacologic or biologic agent

          -  Human Immunodeficiency virus (HIV) infected or infected with another immunodeficiency
             virus

          -  Hypersensitivity to murine products or the study drugs or their formulations

          -  Inability to measure height accurately

          -  Pregnant or breastfeeding
Clinical trial NCT01128985 (phase 1, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: canagliflozin 50 mg, canagliflozin 100 mg, canagliflozin 300 mg, placebo
SMILES: [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  All patients must have a diagnosis of T2DM for at least 1 year, but not more than 12
             years prior to Day -1 of the study and be medically stable on the basis of physical
             examination, medical history, laboratory safety test results, vital signs and
             electrocardiogram (ECG) performed at Screening

          -  Patients must be on generally stable approved anti-hypeglycemic agent (AHA) regimen
             (i.e., with no change in medication, or only 1 dose step change in dose) for at least
             2 months prior to the Screening Visit

          -  Patients must have fasting plasma glucose (FPG) concentrations between 7.8 mM (140
             mg/dL) and 15 mM (270 mg/dL) on Day -2

        Exclusion Criteria:

          -  History of clinically significant diabetic complications including retinopathy,
             nephropathy, or macro albuminuria, neuropathy, gastroparesis, or diabetic ketoacidosis

          -  History of type 1 diabetes mellitus (T1DM)

          -  History of repeated severe hypoglycemic episodes before screening
Clinical trial NCT01217957 (phase 1/phase 2, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: ixazomib, lenalidomide, dexamethasone
SMILES: [H][C@@](CC(C)C)(N=C(O)CN=C(O)C1=C(Cl)C=CC(Cl)=C1)B(O)O, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

        Each patient must meet all of the following eligibility criteria to be enrolled in the
        study:

          -  Male or female patients 18 years or older

          -  Previously untreated multiple myeloma diagnosed according to standard criteria
             requiring systemic treatment

          -  Patients must have measurable disease

          -  Nonsecretory multiple myeloma based upon standard M-component criteria (i.e.,
             measurable serum/urine M-component) is not allowed unless the baseline serum free
             light chain level (Freelite™) is evaluated Patients must meet clinical laboratory
             criteria as specified in study protocol

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          -  Female and male patients MUST adhere to the guidelines of the lenalidomide pregnancy
             prevention program

          -  Must be able to take concurrent aspirin 325 mg daily

          -  Voluntary written consent

        Exclusion Criteria

        Patients meeting any of the following exclusion criteria are not to be enrolled in the
        study:

          -  Peripheral neuropathy that is greater or equal to Grade 2

          -  Female patients who are lactating or pregnant

          -  Major surgery or radiotherapy within 14 days before the first dose of study drug

          -  Serious infection requiring systemic antibiotic therapy within 14 days before the
             first dose of study drug

          -  Diarrhea greater than Grade 1 based on the National Cancer Institute Common
             Terminology Criteria for Adverse Events

          -  Central nervous system involvement.

          -  Evidence of current uncontrolled cardiovascular conditions within the past 6 months

          -  Known human immunodeficiency virus (HIV) positive, hepatitis B surface
             antigen-positive status, or known or suspected active hepatitis C infection

          -  Serious medical or psychiatric illness that could, in the investigator's opinion,
             potentially interfere with the completion of treatment according to the protocol

          -  Known gastrointestinal condition that could interfere with swallowing or the oral
             absorption or tolerance of ixazomib

          -  No other prior malignancy within 2 years except nonmelanoma skin cancer or carcinoma
             in situ of any type if they have undergone complete resection
Clinical trial NCT00728936 (phase 1, status: completed)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: imo-2125, saline placebo
SMILES: [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          -  HCV-positive

          -  Nonresponder to standard-dose pegylated interferon-α-2a or -α-2b in combination with
             standard-dose ribavirin

        Exclusion Criteria:

          -  Human immunodeficiency virus (HIV)or hepatitis B surface antigen (HbsAg)

          -  Inadequate bone marrow, liver, and renal function

          -  Treatment with any IFN (interferon)-based or other experimental or antiviral therapies
             within 30 days

          -  Other significant medical diseases

          -  Known alcohol or drug abuse within the past 12 months